US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Kashiv BioSciences, LLC
Kashiv BioSciences Announces Validation and Acceptance of Market Authorization Application by Health Canada for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
June 04, 2026
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
April 22, 2026
From
Kashiv BioSciences, LLC
Via
Business Wire
Tickers
AMRX
Kashiv BioSciences Strengthens Executive Leadership with New Chief Operating Officer and Senior Vice President of Regulatory Affairs
April 14, 2026
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv BioSciences and Intas Pharmaceuticals Sign an Exclusive Licensing and Supply Agreement for Complex Peptide Product in Europe, the UK & India
February 09, 2026
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv BioSciences and JAMP Pharma Corporation Announce the Launch of PEXEGRA® and FILRA® Biosimilars in Canada
September 24, 2025
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv BioSciences and CRISTÁLIA Enter into Licensing and Supply Agreement for Omalizumab Biosimilar (ADL-018) in Latin America
September 11, 2025
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv BioSciences and MS Pharma Enter into MENA License and Supply Agreement for ADL-018, Biosimilar Candidate to XOLAIR® (bOmalizumab)
August 05, 2025
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv BioSciences Announces Positive Topline Results from Confirmatory Efficacy Study of ADL-018, Biosimilar Candidate to XOLAIR® (omalizumab)
June 25, 2025
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv BioSciences Secures $150 Million Debt Financing from GoldenTree Asset Management
April 07, 2025
From
Kashiv BioSciences, LLC
Via
Business Wire
UK Medicines and Healthcare Products Regulatory Agency has Validated and Accepted the Marketing Authorization Application for ADL-018, a Proposed Biosimilar of Xolair® (omalizumab)
March 26, 2025
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv BioSciences, LLC Obtains Marketing Authorization for Pegfilgrastim Injection from Health Canada
February 25, 2025
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002
January 28, 2025
From
Kashiv Biosciences, LLC
Via
Business Wire
Kashiv Biosciences Expands Leadership Team with New Chief Financial Officer and Chief Legal Officer
December 10, 2024
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv BioSciences Appoints Dr. Sandeep Nilkanth Athalye as Global CEO
November 01, 2024
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv BioSciences Announces Completion of Enrollment for Phase III Clinical Trial of ADL018, a Biosimilar Candidate to XOLAIR® (omalizumab)
July 25, 2024
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
July 01, 2024
From
Kashiv BioSciences, LLC
Via
Business Wire
Tickers
AMRX
Kashiv BioSciences Enrolls First Patient in Phase III Clinical Study for ADL018, A Biosimilar Candidate to XOLAIR® (omalizumab)
October 02, 2023
From
Kashiv BioSciences, LLC
Via
Business Wire
Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair® (omalizumab)
July 05, 2023
From
Kashiv Biosciences, LLC
Via
Business Wire
Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA® (pegfilgrastim-pbbk)
May 31, 2022
From
Kashiv Biosciences, LLC
Via
Business Wire
